AU2001273305A1 - Methods and compositions relating to muscle selective calcineurin interacting protein (mcip) - Google Patents

Methods and compositions relating to muscle selective calcineurin interacting protein (mcip)

Info

Publication number
AU2001273305A1
AU2001273305A1 AU2001273305A AU7330501A AU2001273305A1 AU 2001273305 A1 AU2001273305 A1 AU 2001273305A1 AU 2001273305 A AU2001273305 A AU 2001273305A AU 7330501 A AU7330501 A AU 7330501A AU 2001273305 A1 AU2001273305 A1 AU 2001273305A1
Authority
AU
Australia
Prior art keywords
mcip
methods
interacting protein
compositions relating
calcineurin interacting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001273305A
Inventor
Beverly Rothermel
Sanders R. Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of AU2001273305A1 publication Critical patent/AU2001273305A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03016—Phosphoprotein phosphatase (3.1.3.16), i.e. calcineurin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/841—Muscles; heart

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Veterinary Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
AU2001273305A 2000-07-07 2001-07-06 Methods and compositions relating to muscle selective calcineurin interacting protein (mcip) Abandoned AU2001273305A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21660100P 2000-07-07 2000-07-07
US60/216,601 2000-07-07
US09/782,953 US7629308B2 (en) 2000-07-07 2001-02-13 Methods relating to muscle selective calcineurin interacting protein (MCIP)
US09/782,953 2001-02-13
PCT/US2001/021662 WO2002004491A2 (en) 2000-07-07 2001-07-06 Methods and compositions relating to muscle selective calcineurin interacting protein (mcip)

Publications (1)

Publication Number Publication Date
AU2001273305A1 true AU2001273305A1 (en) 2002-01-21

Family

ID=26911155

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001273305A Abandoned AU2001273305A1 (en) 2000-07-07 2001-07-06 Methods and compositions relating to muscle selective calcineurin interacting protein (mcip)

Country Status (6)

Country Link
US (1) US7629308B2 (en)
EP (1) EP1301597A2 (en)
JP (1) JP2004502444A (en)
AU (1) AU2001273305A1 (en)
CA (1) CA2415967A1 (en)
WO (1) WO2002004491A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7629308B2 (en) 2000-07-07 2009-12-08 Board Of Regents, The University Of Texas System Methods relating to muscle selective calcineurin interacting protein (MCIP)
US6524819B1 (en) * 2000-07-11 2003-02-25 Incyte Genomics, Inc. Down syndrome critical region 1-like proteins
CA2425396A1 (en) * 2000-11-07 2002-06-13 Board Of Regents, The University Of Texas System Methods and compositions relating to muscle specific sarcomeric calcineurin-binding proteins (calsarcins)
US20030045679A1 (en) * 2001-07-13 2003-03-06 Crawford Dana R. Calcineurin modulators
US20030186289A1 (en) * 2002-01-22 2003-10-02 Myogen, Inc. Model cell systems for screening of anti-hypertrophic therapeutics
WO2006034184A2 (en) * 2004-09-17 2006-03-30 Myogen, Inc. Use of modulators of a novel form of muscle selective calcineurin interacting protein (mcip-1-38) as a treatment for cardiovascular diseases
KR101807324B1 (en) * 2009-06-26 2017-12-08 큐알엔에이, 인크. Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4330557A (en) * 1979-05-21 1982-05-18 Claudio Cavazza Acyl-carnitine and use thereof in parenteral administration of triglycerides
US5958404A (en) * 1994-04-13 1999-09-28 Research Corporation Technologies, Inc. Treatment methods for disease using co-localized cells and Sertoli cells obtained from a cell line
US5651980A (en) * 1994-04-15 1997-07-29 Biohybrid Technologies, Inc. Methods of use of uncoated gel particles
ES2154506B1 (en) * 1995-06-07 2001-11-16 Estivill Palleja Xavier CHARACTERIZATION PROCEDURE FOR A NEW MOLECULAL CLONING TECHNIQUE (PCR ALU-SPLICE) OF A GENETIC SEQUENCE OF THE HUMAN CHROMOSOME 21 AND NEW DSCRI GENETIC SEQUENCE OF THE CRITICAL SYNDROME DEDOWN OF SUCH CHROMOSOMA, CHARACTERIZED ACCORDING TO THE MACHINE.
JP2001520170A (en) 1997-10-16 2001-10-30 ボード・オヴ・リージェンツ，ザ・ユニヴァーシティ・オヴ・テキサス・システム Animal models for cardiac hypertrophy and treatment methods related to NF-AT3 function
AUPP263498A0 (en) 1998-03-27 1998-04-23 Walter And Eliza Hall Institute Of Medical Research, The Novel therapeutic molecules and uses therefor
AU5483599A (en) 1998-08-14 2000-03-06 Board Of Regents, The University Of Texas System Calcineurin-dependent control of skeletal muscle fiber type
CA2378643A1 (en) * 1999-07-23 2001-02-01 Diacrin, Inc. Muscle cells and their use in cardiac repair
US7629308B2 (en) 2000-07-07 2009-12-08 Board Of Regents, The University Of Texas System Methods relating to muscle selective calcineurin interacting protein (MCIP)

Also Published As

Publication number Publication date
US20020150953A1 (en) 2002-10-17
WO2002004491A3 (en) 2003-01-30
EP1301597A2 (en) 2003-04-16
CA2415967A1 (en) 2002-01-17
WO2002004491A2 (en) 2002-01-17
JP2004502444A (en) 2004-01-29
US7629308B2 (en) 2009-12-08

Similar Documents

Publication Publication Date Title
AU2002230831A1 (en) Compositions of human proteins and method of use thereof
AU2001276048A1 (en) Rapid-melt semi-solid compositions, methods of making same and methods of using same
AU2001279284A1 (en) Rapid-melt semi-solid compositions, methods of making same and methods of using same
AU2001294808A1 (en) Catecholamine pharmaceutical compositions and methods
AUPP968699A0 (en) Therapeutic compositions and method for their preparation
AU2002219988A1 (en) Compositions and methods relating to breast specific genes and proteins
AU2002243972A1 (en) Compositions and methods relating to breast specific genes and proteins
AU2001273305A1 (en) Methods and compositions relating to muscle selective calcineurin interacting protein (mcip)
AU2002345878A1 (en) Ilt3 and ilt4-related compositions and methods
AU2001297741A1 (en) Compositions and methods relating to breast specific genes and proteins
AU2001245896A1 (en) Maize glycine rich protein promoter compositions and methods for use thereof
WO2002077233A8 (en) 38650, 28472, 5495, 65507, 81588 and 14354 METHODS AND COMPOSITIONS OF HUMAN PROTEINS AND USES THEREOF
AU2001265280A1 (en) Preparation of 2-hydroxy-5-oxoproline and analogs thereof
AU2002364696A8 (en) Crystalline neutrokine-alpha protein, method of preparation thereof, and method of use thereof
AU2001253336A1 (en) Method 0f administration of paclitaxel-plasma protein formulation
AU2002237733A1 (en) Methods and compositions relating to muscle specific sarcomeric calcineurin-binding proteins (calsarcins)
AU2001297804A1 (en) Compositions and methods relating to breast specific genes and proteins
AU2001297794A1 (en) Methods and compositions of human proteins and uses thereof.
AU2001259564A1 (en) Pharmaceutical compositions and methods for use
AUPQ599500A0 (en) Novel peptides, modulatory agents therefor and methods of using them
AU2002236534A1 (en) Compositions and methods relating to ovary specific genes and proteins
AU2002253946A1 (en) Compositions and methods relating to breast specific genes and proteins
AUPQ876400A0 (en) Compositions and method of using them
AU2002245158A1 (en) Human proteins 55562 and 21617, and methods of use thereof
AU2002225852A1 (en) "67118", "67067" and "62092", human proteins and methods of use thereof